Trial Profile
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary) ; Temozolomide
- Indications Ewing's sarcoma; Neuroectodermal tumours; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jan 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2018 Planned primary completion date changed from 31 Oct 2018 to 1 Mar 2020.
- 12 Jun 2018 Status changed from suspended to active, no longer recruiting.